Piper Sandler analyst Biren Amin maintains Compass Therapeutics (NASDAQ:CMPX) with a Overweight a

Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.13) per share which missed the a

The Company expects feedback from the FDA this quarter regarding the COMPANION-002 Phase 2/3 data fo

Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical compa

BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stag

Compass Therapeutics is rated Buy, with risk/reward favoring upside after a sharp post-data selloff.

Compass Therapeutics, Inc. (CMPX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference

Compass Therapeutics NASDAQ: CMPX Chief Executive Officer Tom Schuetz said the company is preparing

BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage

CTX-8371, a novel dual checkpoint blocker that simultaneously targets the programmed death receptor

BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutic

NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutic

NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest

BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage

NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors o

Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.10) per share which met the anal

As recently announced, tovecimig (DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel

NEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor

Canaccord Genuity analyst John Newman maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and

Citizens analyst Reni J. Benjamin reiterates Compass Therapeutics (NASDAQ:CMPX) with a Market Out

Compass Therapeutics, Inc. (CMPX) Discusses Positive Secondary Endpoint Results From COMPANION-002 S

SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims

HC Wainwright & Co. analyst Joseph Pantginis reiterates Compass Therapeutics (NASDAQ:CMPX) wi

U.S. stocks trade lower on Monday, with Dow falling 0.1%. Verizon beats Q1 earnings, raises FY26 gui

Compass Therapeutics says tovecimig misses overall survival endpoint in biliary tract cancer study,

US stocks mixed on Monday, Nasdaq falls 0.56% while Dow gains 0.06%. Energy shares up 1%. Domino&#39

U.S. stock futures mixed with Dow futures down 0.1%. Domino's Pizza misses earnings expectations

Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical compa

QCOM: 13% | OpenAI Eyes 'AI Agent' Smartphone With Qualcomm And MediaTek, Targets App-Free E

Organon & Co (OGN) jumped 14.8% in pre-market trading as Sun Pharma agreed to acquire the compan

Guggenheim analyst Michael Schmidt reiterates Compass Therapeutics (NASDAQ:CMPX) with a Buy and m

Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.09) per share which beat the ana

Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) rose 65.3% to $12.20 in pre-market tradi